The inhibitory effect of dantrolene sodium and propofol on 6-phosphogluconate dehydrogenase from rat erythrocyte

Dantrolene sodium is an inhibitor of a skeletal muscle subtype of ryanodine receptors that stabilizes intracellular calcium concentrations and exerts neuroprotective effects in neurons submitted to excitotoxic challenges. Propofol is a short-acting intravenous anaesthetic. It has widely been used clinically as an intravenous general anaesthetic and as a sedative for critically ill patients. 6-Phosphogluconate dehydrogenase (6PGD) constitutes the pentose phosphate pathway and produces NADPH. It is also considered as a lipogenic gene since NADPH is a pivotal cofactor for lipogenesis. In this study, in vivo inhibition effects of dantrolene sodium and propofol on 6PGD were studied. The 6PGD activity was inhibited in vivo by both dantrolene sodium and propofol. Dantrolene at pharmacological dosage (10 mg/ kg) inhibited the significantly (p≤0.05) 3 h after dosing. However, the enzyme activity has been raised to the normal level at 5 h. On the other hand, at the pharmacological dosage (5 mg/kg), propofol also inhibited the significantly 1 h (p<0.05) and 3 h (p<0.05) after dosing. However, the enzyme activity has been raised to the normal level at 5 h.